title: Recruitment of human cord blood-derived endothelial colony-forming cells to sites of tumor angiogenesis.
abstract: OBJECTIVE
  Endothelial progenitor cells (EPCs) specifically home to sites of malignant growth, rendering them attractive for anti-cancer therapies. Data are conflicting on the phenotype and quantitative contribution toward tumor angiogenesis based on differing culture assays to outgrow EPCs. To evaluate the origin and early phenotype of EPCs and to define a population with enhanced tumor-targeting capacity, we evaluated a hierarchy of cord blood-derived EPCs modeling the multi-step nature of tumor homing.
  
  
  METHODS
  CD34(+) mononuclear cells were isolated from fresh cord blood and cultured to derive endothelial colony-forming cells (ECFCs). Human umbilical vein endothelial cells (HUVECs) served as control. Using intra-vital microscopy, the recruitment was analyzed in mice bearing C6 xenografts. Adhesion, migration, transmigration and differentiation were further addressed.
  
  
  RESULTS
  Within the primary passage, ECFCs underwent a rapid maturation from a CD45(+) and CD31(+) phenotype to a CD45(-) and endothelial marker positive phenotype. Assessing in vivo tumor recruitment, ECFCs had the highest activity in all steps analyzed. In vitro, ECFCs demonstrated significantly higher adhesion under static and flow conditions. Similarly, ECFCs exhibited highest migratory and trans-migratory activity toward tumor-conditioned medium. On subcutaneous implantation, only ECFCs formed blood vessels covered with perivascular cells, similar to HUVECs.
  
  
  CONCLUSIONS
  Our study indicates that ECFCs emerge from a CD45(+) and CD31(+) progenitor and rapidly mature in culture. ECFCs have a significantly higher potential for tumor targeting than non-cultured CD34(+) cells and HUVECs. They are ideal candidates for future cell-based anti-cancer therapies.
authors.affiliation: Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. karen.bieback@medma.uni-heidelberg.de
authors.forename: Karen
authors.initials: K
authors.lastname: Bieback
authors.forename: Maria
authors.initials: M
authors.lastname: Vinci
authors.forename: Susanne
authors.initials: S
authors.lastname: Elvers-Hornung
authors.forename: Arne
authors.initials: A
authors.lastname: Bartol
authors.forename: Torsten
authors.initials: T
authors.lastname: Gloe
authors.forename: Marcus
authors.initials: M
authors.lastname: Czabanka
authors.forename: Harald
authors.initials: H
authors.lastname: Klüter
authors.forename: Hellmut
authors.initials: H
authors.lastname: Augustin
authors.forename: Peter
authors.initials: P
authors.lastname: Vajkoczy
mesh_terms: D000818:Animals; D018952:Antigens, CD34; D002454:Cell Differentiation; D042783:Endothelial Cells / Q000166:cytology / Q000637:transplantation*; D004730:Endothelium, Vascular / Q000166:cytology; D005312:Fetal Blood / Q000166:cytology / Q000637:transplantation*; D005910:Glioma / Q000473:pathology / Q000628:therapy; D061307:Human Umbilical Vein Endothelial Cells / Q000166:cytology; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000166:cytology; D051379:Mice; D009389:Neovascularization, Pathologic / Q000235:genetics / Q000628:therapy*; D051381:Rats; D033581:Stem Cell Transplantation; D013234:Stem Cells / Q000166:cytology; D014183:Transplantation, Heterologous
chemical_list: D018952:Antigens, CD34